investors.alnylam.com investors.alnylam.com

investors.alnylam.com

Alnylam Pharmaceuticals, Inc. - Investor Relations

Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. 069 ( 0.66%). Data as of 4:00 PM ET on 08.14.2015. Minimum 20 Minute Delay. Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities. Alnylam to Webcast Presentation at Canaccord Genuity 35th Annual Growth Conference. Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results. 08202015 at 9:00 AM ET. 08142015 at 2:00 PM ET.

http://investors.alnylam.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR INVESTORS.ALNYLAM.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

June

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Friday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.9 out of 5 with 7 reviews
5 star
2
4 star
2
3 star
3
2 star
0
1 star
0

Hey there! Start your review of investors.alnylam.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.7 seconds

CONTACTS AT INVESTORS.ALNYLAM.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Alnylam Pharmaceuticals, Inc. - Investor Relations | investors.alnylam.com Reviews
<META>
DESCRIPTION
Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. 069 ( 0.66%). Data as of 4:00 PM ET on 08.14.2015. Minimum 20 Minute Delay. Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities. Alnylam to Webcast Presentation at Canaccord Genuity 35th Annual Growth Conference. Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results. 08202015 at 9:00 AM ET. 08142015 at 2:00 PM ET.
<META>
KEYWORDS
1 menu
2 skip to content
3 patients
4 patient connect attr
5 patient connect hemophilia
6 patient connect porphyria
7 investors
8 overview
9 stock information
10 corporate governance
CONTENT
Page content here
KEYWORDS ON
PAGE
menu,skip to content,patients,patient connect attr,patient connect hemophilia,patient connect porphyria,investors,overview,stock information,corporate governance,sec filings,fundamentals,shareholder information,earnings estimates,ownership profile,events
SERVER
Microsoft-IIS/6.0
POWERED BY
ASP.NET
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Alnylam Pharmaceuticals, Inc. - Investor Relations | investors.alnylam.com Reviews

https://investors.alnylam.com

Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. 069 ( 0.66%). Data as of 4:00 PM ET on 08.14.2015. Minimum 20 Minute Delay. Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities. Alnylam to Webcast Presentation at Canaccord Genuity 35th Annual Growth Conference. Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results. 08202015 at 9:00 AM ET. 08142015 at 2:00 PM ET.

INTERNAL PAGES

investors.alnylam.com investors.alnylam.com
1

Alnylam Pharmaceuticals, Inc. - Shareholder Briefcase Registration

http://investors.alnylam.com/briefcase.cfm

Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. Collect, zip and download files from our Investor Relations website. Click on the briefcase icon. Located near most downloadable files throughout our IR website and use this page to manage your briefcase. Please fill in the form below to access this feature. *. Fixed Income Analyst (sell-side). Fixed Income Analyst (buy-side). Portfolio Manager (Fixed Income). Type in number *. Minimum 20 Minute Delay.

2

Alnylam Pharmaceuticals, Inc. - Investor Relations

http://investors.alnylam.com/index.cfm

Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. Data as of 12:03 PM ET on 08.19.2016. Minimum 20 Minute Delay. Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress. 08222016 at 10:30 AM ET.

3

Alnylam Pharmaceuticals, Inc. - Corporate Governance

http://investors.alnylam.com/governance.cfm

Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. Nominating and Corporate Governance Committee Charter. Science and Technology Committee Charter. Code of Business Conduct and Ethics. Add file to Briefcase. Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Data as of 12:03 PM ET on 08.19.2016. Minimum 20 Minute Delay.

4

Alnylam Pharmaceuticals, Inc. - Stock Information

http://investors.alnylam.com/stockquote.cfm

Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). 12:03 PM ET on 08.19.2016. Sign up for e-mail alerts. Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress.

5

Alnylam Pharmaceuticals, Inc. - SEC Filings

http://investors.alnylam.com/sec.cfm

Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. Starr, kevin p. Sharp, philip a. Schulman, amy w. Pyott, david e i. Paul, steven m. Clarke, john k. Bonney, michael w. Ausiello, dennis a. Showing 1-20 of 803. Add PDF file to Briefcase. Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Minimum 20 Minute Delay.

UPGRADE TO PREMIUM TO VIEW 15 MORE

TOTAL PAGES IN THIS WEBSITE

20

LINKS TO THIS WEBSITE

alnylam.com alnylam.com

Beta-Thalassemia – Alnylam

http://www.alnylam.com/product-pipeline/other-genetic-medicines

Delivery of RNAi Therapeutics. Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Access to Investigational Drugs. Free Third-Party Generic Screening and Counseling Programs. Patient Connect E-Mail Alert Sign Up. Access to Investigational Drugs. Delivery of RNAi Therapeutics. Genetic Medicine Strategic Therapeutic Area (STAr). Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Reduced hemoglobin production also leads to iron ov...

alnylam.com alnylam.com

Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) – Alnylam

http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fap

Delivery of RNAi Therapeutics. Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Access to Investigational Drugs. Free Third-Party Generic Screening and Counseling Programs. Patient Connect E-Mail Alert Sign Up. Access to Investigational Drugs. Delivery of RNAi Therapeutics. Genetic Medicine Strategic Therapeutic Area (STAr). Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Specifically, hereditary ATTR amyloidosis with poly...

alnylam.com alnylam.com

Corporate Overview – Alnylam

http://www.alnylam.com/who-we-are/corporate-overview

Delivery of RNAi Therapeutics. Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Access to Investigational Drugs. Free Third-Party Generic Screening and Counseling Programs. Patient Connect E-Mail Alert Sign Up. Access to Investigational Drugs. Delivery of RNAi Therapeutics. Genetic Medicine Strategic Therapeutic Area (STAr). Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). View our Corporate Presentation.

alnylam.com alnylam.com

Strategic Alliances – Alnylam

http://www.alnylam.com/our-approach/strategic-alliances

Delivery of RNAi Therapeutics. Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Access to Investigational Drugs. Free Third-Party Generic Screening and Counseling Programs. Patient Connect E-Mail Alert Sign Up. Access to Investigational Drugs. Delivery of RNAi Therapeutics. Genetic Medicine Strategic Therapeutic Area (STAr). Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). The venture philanthropy subsidiary of the Alpha-1 ...

jobs-alnylam.icims.com jobs-alnylam.icims.com

Careers – Alnylam

https://jobs-alnylam.icims.com/capella

90% employer-paid, top-tier PPO. 100% employer-paid tuition reimbursement. 90 - 100% employer-paid transportation program.

alnylam.com alnylam.com

About Alnylam – Alnylam

http://www.alnylam.com/our-approach/about-alnylam

Delivery of RNAi Therapeutics. Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Access to Investigational Drugs. Free Third-Party Generic Screening and Counseling Programs. Patient Connect E-Mail Alert Sign Up. Access to Investigational Drugs. Delivery of RNAi Therapeutics. Genetic Medicine Strategic Therapeutic Area (STAr). Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). The opportunity to monitor an early, blood-based bi...

alnylam.com alnylam.com

Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM) – Alnylam

http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac

Delivery of RNAi Therapeutics. Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Access to Investigational Drugs. Free Third-Party Generic Screening and Counseling Programs. Patient Connect E-Mail Alert Sign Up. Access to Investigational Drugs. Delivery of RNAi Therapeutics. Genetic Medicine Strategic Therapeutic Area (STAr). Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Specifically, hereditary ATTR amyloidosis with card...

alnylam.com alnylam.com

Our Culture – Alnylam

http://www.alnylam.com/who-we-are/our-culture

Delivery of RNAi Therapeutics. Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Access to Investigational Drugs. Free Third-Party Generic Screening and Counseling Programs. Patient Connect E-Mail Alert Sign Up. Access to Investigational Drugs. Delivery of RNAi Therapeutics. Genetic Medicine Strategic Therapeutic Area (STAr). Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). For all the great details on our programs! Alnylam ...

alnylam.com alnylam.com

Management Board – Alnylam

http://www.alnylam.com/management

Delivery of RNAi Therapeutics. Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Access to Investigational Drugs. Free Third-Party Generic Screening and Counseling Programs. Patient Connect E-Mail Alert Sign Up. Access to Investigational Drugs. Delivery of RNAi Therapeutics. Genetic Medicine Strategic Therapeutic Area (STAr). Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). SVP, Chief Human Resources Officer.

alnylam.com alnylam.com

Complement-Mediated Disease – Alnylam

http://www.alnylam.com/product-pipeline/complement-mediated-disease

Delivery of RNAi Therapeutics. Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM). Access to Investigational Drugs. Free Third-Party Generic Screening and Counseling Programs. Patient Connect E-Mail Alert Sign Up. Access to Investigational Drugs. Delivery of RNAi Therapeutics. Genetic Medicine Strategic Therapeutic Area (STAr). Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN). Complement component C5 which is predominantly expr...

UPGRADE TO PREMIUM TO VIEW 120 MORE

TOTAL LINKS TO THIS WEBSITE

130

SOCIAL ENGAGEMENT



OTHER SITES

investors.algonquinpower.com investors.algonquinpower.com

IRWeblink

Thank you for your interest in IR Solutions. You have reached this page because the URL you have requested is no longer available, or you do not have permission to view it. For more information on the most comprehensive IR web site management tool available, please click here. If you have any questions, e-mail IRSupport@snl.com. Or call (866) 802-9128 and ask for an IR Solutions sales representative. To return to the main SNL Financial homepage.

investors.all-starsportscenter.com investors.all-starsportscenter.com

All-Star Sports Center - Investors

All-Star Sports Center - Investors. Http:/ investors.all-starsportscenter.com/.

investors.alliancehealthcareservices-us.com investors.alliancehealthcareservices-us.com

Alliance HealthCare Services | Investors | Company Overview

Click here to bypass content and jump to site navigation. Pay Your Bill Online. About Alliance HealthCare Services. Q2 2015 Alliance HealthCare Services Earnings Conference Call. 160;at 5:00 pm ET. Q2 2015 Alliance HealthCare Services Earnings Conference Call. Thursday, August 6, 2015 . 5:00 pm ET  . Click here for webcast. Click here to add this event to your calendar. 160; 0.35. Data as of 08/14/15 4:00 pm ET. Minimum 20 minute delay. Alliance HealthCare Services Reports Second Quarter 2015 Results.

investors.alliedminds.com investors.alliedminds.com

Overview | Allied Minds

Skip to main content. 100 High Street, 28th Floor. Boston, MA 02110. 100 High Street, 28th Floor. Boston, MA 02110. Allied Minds is a diversified holding company focused on venture creation within the life science and technology sectors. With unparalleled access to hundreds of university and federal labs across the U.S., Allied Minds forms, funds, and operates a portfolio of companies to disrupt existing markets and generate significant value for its investors and stakeholders.

investors.allot.com investors.allot.com

Investor Center | Allot

105;nfo@allot.com. Mobile & MVNO. Network & User Analytics. Cloud & Enterprise. Cloud & Managed Hosting. Awareness & Analytics. Internet & WAN Virtualization. Traffic Management and Optimization. Policy & Charging. Support & Services. Allot 24/7 Support Center. Renew, Expand, Solve. Design & Planning. Operations & Post Deployment. Become an Allot Expert. Become a Channel Partner. Become a Solution Partner. Get to know Allot. Allot in the News. For the Proxy Card filed in addition to the September 16.

investors.alnylam.com investors.alnylam.com

Alnylam Pharmaceuticals, Inc. - Investor Relations

Delivery of RNAi Therapeutics. Hepatitis B Virus Infection. Beta-Thalassemia and Iron Overload Disorders. 069 ( 0.66%). Data as of 4:00 PM ET on 08.14.2015. Minimum 20 Minute Delay. Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities. Alnylam to Webcast Presentation at Canaccord Genuity 35th Annual Growth Conference. Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results. 08202015 at 9:00 AM ET. 08142015 at 2:00 PM ET.

investors.alphatecspine.com investors.alphatecspine.com

Investor Relations | Alphatec Spine, Inc.

Skip to main navigation. Skip to primary navigation. We improve lives by providing innovative spine surgery solutions through our relentless pursuit of superior outcomes. Working at Alphatec Spine. Contributing at Alphatec Spine. Collaborating at Alphatec Spine. Opportunities at Alphatec Spine. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put ATEC's financial performance into perspective. Mar 19, 2018.

investors.amadeus.com investors.amadeus.com

Amadeus

Investors, Amadeus IT Holding SA. Travel Further, Corporate Responsibility. Financial reports and presentations. CNMV and other regulatory bodies. Our transaction-based pricing model allows our customers to convert certain fixed technology costs into variable costs that vary with passenger volumes; it also links our revenue to global travel volumes rather than travel spending, thus reducing the volatility of our operating results. Investor relations at Amadeus. Very often question, where to buy viagra.

investors.amcnetworks.com investors.amcnetworks.com

Investors | AMC Networks

Delayed at least 20 minutes. Dedicated to producing quality programming and movie content for more than 30 years. Mar 29, 2018 at 4:00 PM ET. Intraday data provided by eSignal. Mar 1, 2018. AMC Networks Inc. Reports Full Year and Fourth Quarter 2017 Results. Feb 26, 2018. AMC Networks Inc. Announces Proposal to Acquire RLJ Entertainment, Inc. Feb 21, 2018. AMC Networks to Participate in Deutsche Bank Media, Telecom and Business Services Conference. Mar 6, 2018 at 3:00 PM. Mar 1, 2018 at 10:00 AM ET.

investors.amdocs.com investors.amdocs.com

Amdocs Investors Relations: Investor Relations

Amdocs: Embrace Challenge, Experience Success. For more information, visit Amdocs at www.amdocs.com. Amdocs Limited Reports Record Quarterly Revenue of $908M. Second Quarter Results for Fiscal 2015. Amdocs Limited Reports Record Quarterly Revenue of $908M. Second Quarter Results for Fiscal 2015. 08/07/15 4:00 pm ET. 160;- 0.25. 30 Years of Excellence. Corporate Social Responsibility Report. Amdocs and Corporate Social Responsibility. The Yellow Pages Years. Customer Care and Billing.

investors.amedica.com investors.amedica.com

Investor Relations - AMEDICA

Bull; Contact Us. Bull; 855.839.3500 (Toll-Free). How Silicon Nitride Compares. Explore Fusion with Silicon Nitride. Valeo Interbody Fusion Devices. Valeo C Interbody Fusion Device. Valeo II PL/OL Interbody Fusion Device. Valeo PL Interbody Fusion Device. Valeo OL Interbody Fusion Device. Valeo TL Interbody Fusion Device. Valeo AL II Interbody Fusion Device. Preference 2 Pedicle Screw System. Preference 2 Pedicle Screw System. Tercet Triple-lead Pedicle Screws. Preference 2 Complex Spine System. Investor...